• Careers
  • Contact
Synthekine
  • About Us
    • Our Story
    • About Cytokines
    • Leadership Team
    • Board of Directors
    • Our Partners
  • Our Pipeline
    • Pipeline
    • STK-012
    • Legacy Programs
    • Cytokine Engineering Platforms
  • For Patients
    • SYNERGY-101 Phase 2 Study in Non-Small Cell Lung Cancer
    • Expanded Access Policy
  • News
    • Press Releases
    • Posters and Publications
  • Twitter
  • Linked In
  • Menu Menu
  • About Us
    • Our Story
    • About Cytokines
    • Leadership Team
    • Board of Directors
    • Our Partners
  • Our Pipeline
    • Pipeline
    • STK-012
    • Legacy Programs
    • Cytokine Engineering Platforms
  • For Patients
    • SYNERGY-101 Phase 2 Study in Non-Small Cell Lung Cancer
    • Expanded Access Policy
  • News
    • Press Releases
    • Posters and Publications
  • Careers
  • Contact
  • Twitter
  • Linked In

about

January 10, 2022/by David Anderson

Share this entry
  • Share on Facebook
  • Share on X
  • Share on WhatsApp
  • Share on Pinterest
  • Share on LinkedIn
  • Share on Tumblr
  • Share on Vk
  • Share on Reddit
  • Share by Mail
/wp-content/uploads/logo-300x63.png 0 0 David Anderson /wp-content/uploads/logo-300x63.png David Anderson2022-01-10 12:22:232022-01-10 12:22:23about
  • About Us
    • Our Story
    • About Cytokines
    • Leadership Team
    • Board of Directors
    • Our Partners
  • Our Pipeline
    • Pipeline
    • STK-012
    • Legacy Programs
    • Cytokine Engineering Platforms
  • For Patients
    • SYNERGY-101 Phase 2 Study in Non-Small Cell Lung Cancer
    • Expanded Access Policy
  • News
    • Press Releases
    • Posters and Publications
  • Twitter
  • Linked In
  • Careers
  • Contact

Copyright 2026 – Synthekine | Privacy Policy |

Scroll to top Scroll to top Scroll to top